Premier (PINC) Proxy Filing summary

Executive summary

• Agreement reached to be acquired by Patient Square Capital for $28.25 per share in cash, transitioning to a private company upon closing.

• Board unanimously determined the transaction is in the best interests of stockholders, delivering immediate and certain value.

• Transaction expected to close by the first quarter of calendar year 2026, subject to stockholder and regulatory approvals.

• Enhanced financial flexibility and access to capital anticipated to accelerate product innovation and tech enablement.

• Forward-looking statements highlight potential benefits, growth, and risks associated with the transaction.

Voting matters and shareholder proposals

• Stockholders will vote on the proposed acquisition; approval is required for the transaction to proceed.

• Proxy statement and related materials will be filed with the SEC and made available to stockholders.

Board of directors and corporate governance

• Board considered a range of strategic alternatives before unanimously approving the transaction.

• Directors, executive officers, and employees may participate in the proxy solicitation.

• Information on board and executive compensation, as well as security ownership, is available in the 2024 annual meeting proxy statement.